David C. Zebrowski, Ph.D.
Founder, Chief Executive Officer

• David brings over 20 years experience in the field of molecular cardiology and drug development both in academia and pharma R&D.

​

• David received his B.Sc. from Carnegie Mellon University (USA) and Ph.D. from Rutgers Medical School (USA) before going on to pursue academic postdoctoral fellowships at Harvard Medical School/Boston Children´s Hospital/Department of Pediatric Cardiology (USA) and then at the Max Planck Institute of Heart and Lung Research (Germany) where he made novel contributions to the cardiac regeneration field. 

​

• Upon completion of his academic fellowships, David transitioned to the pharmaceutical industry first at AstraZeneca CVMD/Integrated Cardio Metabolic Centre/Karolinksa Institute (Sweden) and then Novo Nordisk Cardiovascular Division (Denmark) where he identified and developed heart failure targets and therapeutic candidates as part of their early target identification leadership team.

​

• Aiming to combine both his academic and pharma experiences to accelerate discovery and development of novel heart failure therapeutics, David returned to academia as an Assistant Professor (tenure track) at the Chinese University of Hong Kong (CUHK)/Hong Kong Children’s Hospital (Hong Kong, SAR, PRC) in the Faculty of Medicine, Department of Medicine and Therapeutics. While at CUHK, David was a grant recipient of internationally reviewed awards from both the Hong Kong Research Grants Council (RGC) and Hong Kong Health and Medical Research Fund (HMRF).

​​

• In 2022, David returned to the USA and founded GenKardia Inc., where he currently serves full-time as CEO.